SPRAVATO®
Treatment for Depression
What is Spravato®?
Spravato® (esketamine) is an FDA-approved nasal spray used alongside an oral antidepressant for adults with treatment-resistant depression. Unlike traditional antidepressants, Spravato works on NMDA receptors in the brain and may provide relief more quickly for some patients.
-
Treatment is administered in-office under medical supervision
Sessions typically occur twice weekly during the initial phase
Each visit lasts approximately 2 hours for monitoring
Patients will need transportation home after each session
-
You May be a candidate if you:
Have been diagnosed with depression
Have tried two or more antidepressants without sufficient relief
Are looking for a new, evidence-based treatment option
-
Experiences and compassionate care team
Personalized treatment planning
Comfortable, monitored clinical environment
Treatment provided in individual private offices for comfort and privacy
Dedicated support throughout your treatment journey
Meet Your Care Team
Jessica Waters
PA-C, CAQ Prescriber
Oversees your treatment plan and evaluates your progress.
Corrinne Miuccio
Prescriber Liaison
Helps coordinate care and guides
you through the process.
Rochelle Reyngold
RN, Spravato® Nurse
Provides in-office care and monitoring during each treatment session.
Safety & Monitoring
Spravato® is available only through a specialized program to ensure patient safety.
Our trained staff closely monitors you during and after each treatment session.
Get Started Today!
Take the Next Step Toward Relief.
